2020
Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy
Ginter PS, Idress R, D’Alfonso T, Fineberg S, Jaffer S, Sattar AK, Chagpar A, Wilson P, Harigopal M. Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. Modern Pathology 2020, 34: 701-709. PMID: 33077923, PMCID: PMC7987728, DOI: 10.1038/s41379-020-00698-2.Peer-Reviewed Original ResearchDiscordant anti‐SARS‐CoV‐2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein
Ko CJ, Harigopal M, Gehlhausen JR, Bosenberg M, McNiff JM, Damsky W. Discordant anti‐SARS‐CoV‐2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. Journal Of Cutaneous Pathology 2020, 48: 47-52. PMID: 32895985, DOI: 10.1111/cup.13866.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 spike proteinCOVID toesEccrine epitheliumEndothelial cellsSkin biopsiesSpike proteinReverse transcriptase polymerase chain reaction testingSARS-CoV-2 antibodiesPolymerase chain reaction testingSARS-CoV-2 RNAPotential pathogenetic mechanismsPositive immunohistochemical labelingSARS-CoV-2Endothelial depositionPathogenetic mechanismsImmunohistochemical stainingReaction testingImmunohistochemical labelingEccrine glandsRNA ISHImmunohistochemistrySpike RNAGold standardTissue sectionsBiopsyPerniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2
Ko CJ, Harigopal M, Damsky W, Gehlhausen JR, Bosenberg M, Patrignelli R, McNiff JM. Perniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2. Journal Of Cutaneous Pathology 2020, 47: 997-1002. PMID: 32745281, PMCID: PMC7436569, DOI: 10.1111/cup.13830.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChilblainsCOVID-19FemaleHumansImmunohistochemistryMaleMiddle AgedSARS-CoV-2ConceptsSARS-CoV-2 nucleocapsid proteinPerivascular lymphocytesImmunohistochemical stainingCOVID-19 pandemicSARS-CoV-2 immunohistochemistryNucleocapsid proteinSARS-CoV-2Inflammatory lesionsHistopathologic findingsIntravascular occlusionMicroscopic findingsPerniosisIntravascular materialLymphocytesLesionsPatientsStainingPandemicSuch casesCuffingHistopathologyCasesImmunohistochemistryFindingsProteinHigh frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers
Yoon EC, Wilson P, Zuo T, Pinto M, Cole K, Harigopal M. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Human Pathology 2020, 102: 13-22. PMID: 32565323, DOI: 10.1016/j.humpath.2020.06.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNon-TNBC casesFrequency of p16TNBC casesAndrogen receptorBreast cancerTissue microarrayAggressive clinical courseAndrogen receptor expressionInvasive ductal carcinomaHistologic grade 3Basal-like breast cancer subtypeNovel prognostic markerBreast cancer subtypesExpression of p16Clinical courseCytokeratin 5/6Ductal carcinomaPrognostic markerReceptor expressionRoutine biomarkersSignificant statistical differenceClinical dataGrade 3Cancer subtypes
2017
Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?
Chagpar AB, Cicek AF, Harigopal M. Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients? The American Surgeon 2017, 83: 704-708. PMID: 28738939, DOI: 10.1177/000313481708300725.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNegative marginsCancer patientsPrimary tumor markersInvasive tumor sizePrimary tumor tissuesMedian invasive tumor sizeInitial surgeryOccult cancerOccult diseaseProspective trialInitial resectionMultifocal diseasePartial mastectomyDuctal carcinomaTumor sizeCavity shavesStage 0Independent pathologistsTumor markersTissue microarrayFurther diseasePatientsTumor tissueDiseaseEconomic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2015
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal Of Medicine 2015, 373: 503-510. PMID: 26028131, PMCID: PMC5584380, DOI: 10.1056/nejmoa1504473.Peer-Reviewed Original ResearchConceptsCavity shave marginsPositive marginsPartial mastectomyShave marginsDuctal carcinomaBreast cancerInvasive cancerOutcome measuresStandard partial mastectomySecondary outcome measuresPrimary outcome measureLower ratesRoutine resectionMedian ageClinicopathological characteristicsCavity shavingMargin clearanceSecond surgeryInvasive carcinomaStage 0MastectomyPathological testingPatientsFurther diseaseVolume of tissue
2007
Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome. Journal Of Clinical Oncology 2007, 25: 5418-5425. PMID: 18048824, DOI: 10.1200/jco.2007.12.8033.Peer-Reviewed Original Research
2006
Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray
Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-1684. PMID: 16532435, DOI: 10.1002/cncr.21783.Peer-Reviewed Original ResearchConceptsPancreatic cancer tissue microarrayCancer tissue microarrayTissue microarrayVEGF receptor 1Flt-1Receptor 1Kaplan-Meier survival curvesVascular endothelial growth factor (VEGF) expressionIndependent prognostic factorVascular endothelial growth factorFlk-1Growth factor expressionEndothelial growth factorPrimary antibodyFlt-1 expressionOverall survivalPrognostic factorsWorse survivalAggressive diseaseDisease stagePoor prognosisTumor expressionPancreatic cancerPancreatic adenocarcinomaPrincipal receptor
2002
Aspiration cytology of elastofibroma dorsi: Case report with ultrastructural and immunohistochemical findings
Harigopal M, Seshan SV, DeLellis RA, Yankelevitz D, Vazquez M. Aspiration cytology of elastofibroma dorsi: Case report with ultrastructural and immunohistochemical findings. Diagnostic Cytopathology 2002, 26: 310-313. PMID: 11992374, DOI: 10.1002/dc.10106.Peer-Reviewed Original Research